Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.
Ochre Bio is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: RNA medicines for liver diseases. The founder listed is Quin Wills (Founder/CSO) (Y Combinator directory entry, March 12, 2020).
Sell to companies like Ochre Bio? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2020-03-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ochre Bio.
Free to see. No signup.
More on Ochre Bio and the records around it.
Same batch, Healthcare first.
Get an email when Ochre Bio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ochre Bio raises, hires or launches. No email unless you switch it on.
Watch Ochre Bio →Get the full cited report on Ochre Bio
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ochre Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.
Checked away from the directory entry. What is below does not come from the company's Y Combinator page.
Ochre Bio is developing therapies for the biggest liver health challenges.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ochre Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ochre Bio covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ochre BioYou get an alert in MentionFox the next time this company shows up.
If you're behind Ochre Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry, and from the company's own site, read directly on 2026-09-27 (ochre-bio.com).
Each opens in a new tab, filled in for Ochre Bio. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-ochre-bio